Cargando…

Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors

BACKGROUND/AIM: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for the treatment of various refractory solid tumors during the last two decades. After the demonstration of graft-versus-leukemia (GvL) effect in a leukemic murine model following allo-HSCT from other strai...

Descripción completa

Detalles Bibliográficos
Autores principales: ŞAHİN, Uğur, DEMİRER, Taner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672351/
https://www.ncbi.nlm.nih.gov/pubmed/32178508
http://dx.doi.org/10.3906/sag-1911-112
_version_ 1783611115562860544
author ŞAHİN, Uğur
DEMİRER, Taner
author_facet ŞAHİN, Uğur
DEMİRER, Taner
author_sort ŞAHİN, Uğur
collection PubMed
description BACKGROUND/AIM: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for the treatment of various refractory solid tumors during the last two decades. After the demonstration of graft-versus-leukemia (GvL) effect in a leukemic murine model following allo-HSCT from other strains of mice, graft-versus-tumor (GvT) effect in a solid tumor after allo-HSCT has also been reported in a murine model in 1984. Several trials have reported the presence of a GvT effect in patients with various refractory solid tumors, including renal, ovarian and colon cancers, as well as soft tissue sarcomas [1]. The growing data on haploidentical transplants also indicate GvT effect in some pediatric refractory solid tumors. Novel immunotherapy-based treatment modalities aim at inducing an allo-reactivity against the metastatic solid tumor via a GvT effect. Recipient derived immune effector cells (RDICs) in the antitumor reactivity following allo-HSCT have also been considered as an emerging therapy for advanced refractory solid tumors. CONCLUSION: This review summarizes the background, rationale, and clinical results of immune-based strategies using GvT effect for the treatment of various metastatic and refractory solid tumors, as well as innovative approaches such as haploidentical HSCT, CAR-T cell therapies and tumor infiltrating lymphocytes (TIL).
format Online
Article
Text
id pubmed-7672351
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Scientific and Technological Research Council of Turkey
record_format MEDLINE/PubMed
spelling pubmed-76723512021-09-28 Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors ŞAHİN, Uğur DEMİRER, Taner Turk J Med Sci Article BACKGROUND/AIM: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for the treatment of various refractory solid tumors during the last two decades. After the demonstration of graft-versus-leukemia (GvL) effect in a leukemic murine model following allo-HSCT from other strains of mice, graft-versus-tumor (GvT) effect in a solid tumor after allo-HSCT has also been reported in a murine model in 1984. Several trials have reported the presence of a GvT effect in patients with various refractory solid tumors, including renal, ovarian and colon cancers, as well as soft tissue sarcomas [1]. The growing data on haploidentical transplants also indicate GvT effect in some pediatric refractory solid tumors. Novel immunotherapy-based treatment modalities aim at inducing an allo-reactivity against the metastatic solid tumor via a GvT effect. Recipient derived immune effector cells (RDICs) in the antitumor reactivity following allo-HSCT have also been considered as an emerging therapy for advanced refractory solid tumors. CONCLUSION: This review summarizes the background, rationale, and clinical results of immune-based strategies using GvT effect for the treatment of various metastatic and refractory solid tumors, as well as innovative approaches such as haploidentical HSCT, CAR-T cell therapies and tumor infiltrating lymphocytes (TIL). The Scientific and Technological Research Council of Turkey 2020-11-03 /pmc/articles/PMC7672351/ /pubmed/32178508 http://dx.doi.org/10.3906/sag-1911-112 Text en Copyright © 2020 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article
ŞAHİN, Uğur
DEMİRER, Taner
Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
title Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
title_full Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
title_fullStr Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
title_full_unstemmed Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
title_short Graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
title_sort graft-versus-cancereffect and innovative approaches in the treatment of refractorysolid tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672351/
https://www.ncbi.nlm.nih.gov/pubmed/32178508
http://dx.doi.org/10.3906/sag-1911-112
work_keys_str_mv AT sahinugur graftversuscancereffectandinnovativeapproachesinthetreatmentofrefractorysolidtumors
AT demirertaner graftversuscancereffectandinnovativeapproachesinthetreatmentofrefractorysolidtumors